Skip to content
Menu

HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $27

Benzinga Newsdesk 8 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $25 to $27.

HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $25 to $27.

Read at benzinga.com